Doubling Down on Mutant RAS Can MEK or Break Leukemia.

Cell
Authors
Keywords
Abstract

Targeting of the RAS pathway has long been a critical therapeutic challenge in oncology. Burgess et al. examine how the relative expression of mutant and wild-type KRAS modulates clonal fitness and sensitivity to MEK inhibitors in a model of Kras(G12D) mutant acute myeloid leukemia and propose its use as a predictive biomarker.

Year of Publication
2017
Journal
Cell
Volume
168
Issue
5
Pages
749-750
Date Published
2017 02 23
ISSN
1097-4172
DOI
10.1016/j.cell.2017.02.013
PubMed ID
28235190
Links